NCT03926143 · MORE INFO

Limitations, agreements, and source contact

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies · Source last updated 2023-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: Due to the small sample size and heterogeneous population, survival distributions and the extent of long-term survival in the applicable populations cannot be reliably estimated from the study results. Overall results were reported. Pooling was done because there is only a single patient treated with combination and no summary tables on a single patient.

point Of Contact

email: clinical-trials-contact@bayer.com
organization: Bayer AG
phone: (+)1-888-84 22937
title: Therapeutic Area Head

Complete source fields

certain Agreement

pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: Due to the small sample size and heterogeneous population, survival distributions and the extent of long-term survival in the applicable populations cannot be reliably estimated from the study results. Overall results were reported. Pooling was done because there is only a single patient treated with combination and no summary tables on a single patient.

point Of Contact

email: clinical-trials-contact@bayer.com
organization: Bayer AG
phone: (+)1-888-84 22937
title: Therapeutic Area Head

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice